P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY

• L. I. Gordon,
• D. Hoda,
• L. Shi,
• S. Guo,
• F. F. Liu,
• J. Braverman,
• R. Dubowy,
• L. Peng,
• A. Sehgal

Affiliations

L. I. Gordon

1 Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago

D. Hoda

2 Intermountain Healthcare, Loveland Clinic for Blood Cancer Therapy, Salt Lake City

L. Shi

3 Evidera, Waltham

S. Guo

3 Evidera, Waltham

F. F. Liu

4 Bristol Myers Squibb, Princeton

J. Braverman

4 Bristol Myers Squibb, Princeton

R. Dubowy

5 Bristol Myers Squibb, Seattle

L. Peng

5 Bristol Myers Squibb, Seattle

A. Sehgal

6 University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, United States of America